Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

677 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CD40 pathway activation status predicts response to CD40 therapy in diffuse large B cell lymphoma.
Burington B, Yue P, Shi X, Advani R, Lau JT, Tan J, Stinson S, Stinson J, Januario T, de Vos S, Ansell S, Forero-Torres A, Fedorowicz G, Yang TT, Elkins K, Du C, Mohan S, Yu N, Modrusan Z, Seshagiri S, Yu SF, Pandita A, Koeppen H, French D, Polson AG, Offringa R, Whiting N, Ebens A, Dornan D. Burington B, et al. Among authors: lau jt. Sci Transl Med. 2011 Mar 16;3(74):74ra22. doi: 10.1126/scitranslmed.3001620. Sci Transl Med. 2011. PMID: 21411738
Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma.
Dornan D, Bennett F, Chen Y, Dennis M, Eaton D, Elkins K, French D, Go MA, Jack A, Junutula JR, Koeppen H, Lau J, McBride J, Rawstron A, Shi X, Yu N, Yu SF, Yue P, Zheng B, Ebens A, Polson AG. Dornan D, et al. Blood. 2009 Sep 24;114(13):2721-9. doi: 10.1182/blood-2009-02-205500. Epub 2009 Jul 24. Blood. 2009. PMID: 19633198 Free article.
Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma.
Polson AG, Williams M, Gray AM, Fuji RN, Poon KA, McBride J, Raab H, Januario T, Go M, Lau J, Yu SF, Du C, Fuh F, Tan C, Wu Y, Liang WC, Prabhu S, Stephan JP, Hongo JA, Dere RC, Deng R, Cullen M, de Tute R, Bennett F, Rawstron A, Jack A, Ebens A. Polson AG, et al. Leukemia. 2010 Sep;24(9):1566-73. doi: 10.1038/leu.2010.141. Epub 2010 Jul 1. Leukemia. 2010. PMID: 20596033
DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma.
Li D, Poon KA, Yu SF, Dere R, Go M, Lau J, Zheng B, Elkins K, Danilenko D, Kozak KR, Chan P, Chuh J, Shi X, Nazzal D, Fuh F, McBride J, Ramakrishnan V, de Tute R, Rawstron A, Jack AS, Deng R, Chu YW, Dornan D, Williams M, Ho W, Ebens A, Prabhu S, Polson AG. Li D, et al. Mol Cancer Ther. 2013 Jul;12(7):1255-65. doi: 10.1158/1535-7163.MCT-12-1173. Epub 2013 Apr 18. Mol Cancer Ther. 2013. PMID: 23598530
Modulating Therapeutic Activity and Toxicity of Pyrrolobenzodiazepine Antibody-Drug Conjugates with Self-Immolative Disulfide Linkers.
Pillow TH, Schutten M, Yu SF, Ohri R, Sadowsky J, Poon KA, Solis W, Zhong F, Del Rosario G, Go MAT, Lau J, Yee S, He J, Liu L, Ng C, Xu K, Leipold DD, Kamath AV, Zhang D, Masterson L, Gregson SJ, Howard PW, Fang F, Chen J, Gunzner-Toste J, Kozak KK, Spencer S, Polakis P, Polson AG, Flygare JA, Junutula JR. Pillow TH, et al. Mol Cancer Ther. 2017 May;16(5):871-878. doi: 10.1158/1535-7163.MCT-16-0641. Epub 2017 Feb 21. Mol Cancer Ther. 2017. PMID: 28223423
Stabilizing a Tubulysin Antibody-Drug Conjugate To Enable Activity Against Multidrug-Resistant Tumors.
Staben LR, Yu SF, Chen J, Yan G, Xu Z, Del Rosario G, Lau JT, Liu L, Guo J, Zheng B, Cruz-Chuh JD, Lee BC, Ohri R, Cai W, Zhou H, Kozak KR, Xu K, Lewis Phillips GD, Lu J, Wai J, Polson AG, Pillow TH. Staben LR, et al. Among authors: lau jt. ACS Med Chem Lett. 2017 Sep 5;8(10):1037-1041. doi: 10.1021/acsmedchemlett.7b00243. eCollection 2017 Oct 12. ACS Med Chem Lett. 2017. PMID: 29057047 Free PMC article.
677 results